Feedback / Questions
gotistobart (BNT316) - OncoC4, BioNTech
https://www.globenewswire.com/news-release/2025/12/06/3201090/0/en/BioNTech-and-OncoC4-Announce-Clinically-Meaningful-Overall-Survival-Benefit-for-Selective-Treg-Modulator-Gotistobart-in-Patients-with-Previously-Treated-Squamous-Non-Small-Cell-Lun.html
Dec 6, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next